SOAT1 and autoimmune disease: The development and clinical and preclinical application of small-molecule JAKis and cytokine-targeted biologics have demonstrated that the inhibition of the JAK-STAT pathway can be an efficacious way to treat inflammatory and autoimmune diseases.